Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

SCLC with Pleural Effusions: Is there Benefit to Adding Radiation?
Author
Howard (Jack) West, MD

In my earliest introductory post about SCLC, I described the typical staging breakdown used clinically, which is essentially divided into limited disease SCLC (LD-SCLC), which is typically treated with chemo and chest radiation together, with curative intent, and extensive disease SCLC (ED-SCLC), which is typically treated with chemo alone and is not considered conventionally curable. But one of the murky areas in SCLC staging is the situation of what is limited disease except for a pleural effusion on the same side as the main tumor (called an "ipsilateral" pleural effusion) . In some trials and at some centers, this situation is considered ED-SCLC, while at others, it's considered LD-SCLC. On the diagram below, an ipsilateral pleural effusion is designated as a controversial staging question:

SCLC staging

A recently published report from Japan (abstract here) describes the experience of 63 patients with LD-SCLC and an ipsilateral pleural effusion. This retrospective review of patients over several years who were all treated at the same center compared the outcomes of patients who initially received chemotherapy and then received chest radiation if their effusion had resolved to the experience of patients who didn't receive radiation after their effusion resolved. They also compared the results for these groups to outcomes in the patients whose effusions didn't resolve after chemo.

There were several take-home messages. One is that the patients who had an effusion but otherwise stable disease had a prognosis between that of patients with otherwise completely limited disease and ED-SCLC:

SCLC survival by status

Importantly, there were long-term survivors with LD-SCLC and a pleural effusion, and the survival was better in the patients who had an effusion that resolved compared with an effusion that didn't. This result wasn't surprising, because we have always seen that the people who have more of a response tend to do better than the people who have less of a response. But more important was the finding that of the patients who had their effusion resolve after chemo, the ones who received chest radiation did better than the ones who didn't get radiation:

SCLC survival with RT for effusion

This might suggest that patients with pleural effusions have a greater chance of being cured by receiving radiation along with chemo. While that may be true, only a minority of these patients (42%) had their effusions drained and evaluated for cancer cells. None of the patients who had confirmed cancer cells had an especially prolonged survival, and the patients who did best were the ones who had a confirmed negative tap for cancer cells. The 58% who didn't have their effusions evaluated had a survival in between, likely because they harbored a mix of true malignant effusions and some with effusions for other reasons that didn't actually have cancer in them.

Overall, it may be that patients with true effusions from SCLC (cancer cells in the fluid) could do better with radiation, but since the best survivors were the ones with no malignant cells in their fluid, these patients may have really been LD-SCLC patients without a true malignant effusion and just had inflammation or some other cause. This study suggests that the patients with LD-SCLC and a pleural effusion that isn't confirmed as positive, and who have a good response after chemo, may do better by being presumed to have true LD-SCLC and should get radiation with chemo (and other evidence says to add the radiation earlier rather than later, preferably with the first or second cycle of chemo). But with the results with a confirmed malignant effusion looking decidedly worse than in the cytology-negative and unknown groups, it's not clear to me that radiation is really providing a benefit to people who actually have malignant effusion. Instead, I interpret these results as saying that if someone has an ambiguous effusion, it makes sense to give them the benefit of the doubt and treat it as LD-SCLC, with curative intent, which means adding chest radiation to chemo.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on